Mountain Valley MD Advances Quicksome™ Sublingual Delivery Platform for Compounded Peptide Applications, Reports on Initial Formulation Work Across Multiple Peptides Including BPC-157

BPC-157 and a handful of other peptides just got a boost from Mountain Valley MD’s Quicksome™ sublingual delivery system. Instead of another boring injection, researchers might soon pop a peptide tab under the tongue and get on with their work. Mountain Valley MD says they’re making headway on initial formulations for multiple peptides, with bpc-157 leading the charge.

Sublingual delivery is all about getting research compounds into the system faster and more efficiently. The Quicksome™ platform uses dissolvable films or tablets, aiming for rapid absorption—no needles, less hassle. For researchers juggling multiple compounds, this could streamline studies and open new avenues for peptide research.

Here’s what stands out:

For anyone sourcing peptides or building out new protocols, this tech could shift the workflow. No more reconstitution headaches or cold storage dance—just a film, a tongue, and you’re running your experiment.

Key takeaway: If Quicksome™ lives up to the hype, expect sublingual delivery to get a lot more attention in research. It’s the kind of innovation that could make peptides even more accessible for experimentation. Keep an eye on the vendor directory for updates as these delivery platforms hit the market.

Innovation in peptide delivery isn’t slowing down, and BPC-157 is right at the center of it.